Estimated mean drug response trajectories for six cancer cell lines with BRAF and HRAS mutations.
figureposted on 25.01.2021, 18:50 by Evanthia Koukouli, Dennis Wang, Frank Dondelinger, Juhyun Park
Observed responses (points) and estimated mean trajectory (lines) of cell concentration for cancer cell lines with and without BRAF and HRAS mutations after treatment with the five anticancer compounds examined.
Read the peer-reviewed publication
gene expression markersgene expression dataGDSCpathway enrichment analysiscancer cell line dose-responseregression modelcancer drug response Cancer treatmentsestimate dosage-dependent associationscancer cell linestranscriptome-wide dosage-dependent...cancer drug sensitivityDNA damage responsedose-varying regression modeldosage levelsroledrug responseBRAF